Dr. Cyril B. Frank
Scientific Director
2001-2006

CIHR Mandate
CIHR Grants & Awards Budget
CIHR funding increases over 7 years by Region
CIHR Funding of Four Research Themes
CIHR
Institute Advisory Board
The IMHA Team
Mandate: Advancing the Science of Arthritis, Bone, Muscle, Oral Health, MSK Rehabilitation and Skin
Rationale: Economic Burden of Illness
IMHA's Vision
IMHA's Strategies - 2006
IMHA - Research Projects by Foci
IMHA Strategic Initiative Budget
IMHA Quality of Life Research Award
IMHA Strategic Initiative Budget
CIHR' s Definition of KT
Knowledge Translation and Exchange: Understanding the cycle
What KT is NOT
What KT IS
Examples (outputs) of KT by Sectors
Partnerships
"Partners in KT"

CIHR Mandate

"To excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system..."

CIHR is:

• Government of Canada's health research funding agency
• Supporting the work of up to 10,000 researchers and trainees in universities, teaching hospitals, and research institutes across Canada
• Developing high-quality people, excellent science and training the next generation of health researchers
• Funding research that improves Canadians' health, health care system and quality of life
• Fostering commercialization, moving research discoveries from academic setting to the marketplace

CIHR Grants & Awards Budget
2005/2006 = $700M

CIHR funding increases over 7 years by Region

CIHR Funding of Four Research Themes
2000 - 2006

CIHR

Institute Advisory Board

A complete list of the Institute Advisory Board Members is available on IMHA's website.

The IMHA Team

Mandate: Advancing the Science of Arthritis, Bone, Muscle, Oral Health, MSK Rehabilitation and Skin

Rationale: Economic Burden of Illness
Note: ~ 19% of total burden relevant to IMHA
- plus 7% oral health

IMHA's Vision

To sustain health and enhance quality of life by eradicating pain, suffering and disability caused by arthritis, musculoskeletal, oral health and skin conditions.

IMHA's Strategies - 2006

SWOT 2006

• Mid-Term Review plus our own analysis

Overall Approach

• Consensus building "Tools" 2006

Priorities

• Capacity Building
• Research Priorities
• Knowledge Translation

Targets (2006-2010)

• Capacity
• Priorities (including KT)
• Partnerships and Public Engagement

IMHA - Research Projects by Foci

Oral Health:

• Development of a collaborative team to study the cytotoxic effects of dental curing lights, Richard Price, Dalhousie University
• A scoping review and research synthesis on the organization and delivery of oral health services in long-term care facilities, Michael MacEntee

Skin:

• Treatment of inflammatory skin disease with adoptive cellular gene therapy using hair follicle dermal papilla derived cells as vectors, Kevin McElwee, Vancouver Coastal Health Research Institute (New discoveries)
• Development and application of non-rejectable skin substitute in wound healing, Aziz Ghahary, U of Alberta and UBC (Priority Announcement)

Muscle:

• Kinetic and neuromuscular gait patterns of moderate knee osteoarthritis patients, Kevin Deluzio, UWO
• Development of novel high content screens for investigating gene function in skeletogenesis, Michael Underhill, UBC (Inventions, tools)

MSK Rehabilitation:

• Development and testing of new virtual reality diagnostic tools for deficits in dexterity and coordination for the upper limb to enhance rehabilitation, Mindy Levin, Universite de Montreal (Invention, tools)
• Development and Implementation of an Omni-Directional Treadmill and Virtual Reality Methods for Rehabilitation of Locomotor Disorders, Carol Richards, Universite Laval (Invention, Tools)

Arthritis:

• Priority criteria for hip and knee replacement addressing health services wait times for surgery, Bassam Masri, Michael Dunbar, Clive Duncan, Hans Kreder, UBC + Dalhousie + U of Toronto
• A demonstration project of electronic patient generated data for point of care reporting in the management of rheumatoid arthritis, Claire Bombardier, U of Toronto

Bone:

• Optimal management of older women with distal forearm fractures, Ann Cranney
• Mesenchymal stem cells and biomaterials in bone regeneration: a team approach, Fabio Rossi, UBC (Network)

IMHA Strategic Initiative Budget
Percentage of funds by research foci areas 2005-06

IMHA Quality of Life Research Award
Award Winner 2005-2006

Aileen Davis, Toronto Western Research Institute

Title of Research: Predictors of disability outcomes following revision knee arthroplasty

Research Category: Rehabilitation: Physical Activity, Mobility and Health

Research Summary: Dr. Davis' study will evaluate how factors such as pre-surgery disability, general health status, the classification of revision, co-morbidity, previous experience with surgery, outcome expectations and demographic variables affect physical disability two years and five years following revision TKA. This study also has important implications for determining indications for revision TKA, resource allocation and new policy for the treatment of these patients.

Award Winner 2005-2006

Sophina Abida Jamal, St. Michael's Hospital

Title of Research: The effect of organic nitrates on osteoporosis

Research Category: Bone: Pain, Disability and Chronic Disease

Research Summary: Osteoporosis or "thinning of the bones" affects one in four Canadian women and one in eight Canadian men. Dr. Jamal's research will endeavor to address this issue by exploring whether nitrates, a group of drugs that are widely available, inexpensive, and commonly used to treat chest pain or angina, can prevent osteoporosis thereby improving a women's quality of life.

Overall Award Winner 2005-2006

Andrew Leask, University of Western Ontario

Title of Research: Connective tissue growth factor (CTGF) action in fibroblasts: Cellular and molecular mechanisms

Research Category: Skin - Tissue Injury Repair and Replacement

Research Summary: Fibrotic disease, caused by excessive scarring, represents well over 25 per cent of the economic burden of illness in Canada, and is one of the largest groups of disorders for which there is no effective therapy. Why fibrosis occurs is unknown, and there are no fibrotic therapies. Dr. Leask and his colleagues have discovered a potential mediator of fibrosis, called CTGF, which is over expressed in fibrotic tissues. "The objective of our study," said Leask, "will be to discover what CTGF does, and whether CTGF provides a good framework for developing anti-fibrotic therapies."

IMHA Strategic Initiative Budget
Percentage of funds by research themes 2005-06

CIHR' s Definition of KT

"the exchange, synthesis and ethically-sound application of research findings within a complex set of interactions among researchers and knowledge users... an acceleration of the knowledge cycle; an acceleration of the natural transformation of knowledge into use."

Knowledge Translation and Exchange:
Understanding the cycle

What KT is NOT

KT goes beyond mere dissemination and/or diffusion.

• It is NOT just researchers disseminating or discussing things to each other
• It is NOT just researchers communicating things to an audience (which would be only a one-way, passive process)

What KT IS

KT is an on-going and iterative process requiring active and conscious participation of both researchers and research-users.

• Researchers deliberately get together with end-users with an explicit intent of changing the behaviour (outputs) of both sides

KT has FOCUS and GOALS

• Targets - Sectors (who researchers interact with)
• Outputs - Outcomes (behaviours change in what happens)

Examples (outputs) of KT by Sectors

Health providers/caregivers

• Case reports, clinical trials, practice guidelines, professional communications, meta-analyses and literature syntheses

Policy makers/decision makers in Gov't or Health Admin

• Notes or policy papers, commissioned reports, case studies, literature syntheses, pilot testing new models of care

Private Sector Organizations

• Patents, commissioned studies, clinical trials, commercialized products or services

Consumer/public

• Media products, internet products, marketing materials, patient education materials

Examples (outputs) of KT by Sectors
eg. Health system improvements

Health providers/caregivers

• Case reports, clinical trials, practice guidelines, professional communications, meta-analyses and literature syntheses

Policy makers/decision makers in Gov't or Health Admin

• Notes or policy papers, commissioned reports, case studies, literature syntheses, pilot testing new models of care

Private Sector Organizations

• Patents, commissioned studies, clinical trials, commercialized products or services

Consumer/public

• Media products, internet products, marketing materials, patient education materials

Partnerships

Partners' contributions can include :

• Formulating research agendas
• Providing input into the development of research, research training programs and/or specific projects
• Support of strategic programs (eg. help enhance general or specific capacity, help build general or specific networks or centres, support specific strategic research priorities, strategically advance KT and/or ethics research agenda) -
  *financial or in-kind (eg. Co-op programs, etc)
• Disseminating findings
• Applying and/or evaluating the outcome of research (e.g., products, services, policy advice, etc)

"Partners in KT"

From Consensus Conference through to product development

• Broad interaction/ consultation amongst stakeholders
• International researchers; consumers-patients/ industry/government;
• Development of research agenda/priorities
• 6 Priorities Identified

$6.6 million invested in osteoarthritis - New Emerging Teams
>$5.7 million inversted in pain - Team Grants